{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:23:46Z","timestamp":1787019826186,"version":"build-2736575974"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Despite widespread use of second-generation cholinesterase inhibitors for the symptomatic treatment of Alzheimer\u2019s disease (AD), little is known about the long term effects of cholinergic treatment on global cognitive function and potential specific effects in different cognitive domains. The objectives of this study were to determine the association between cholinergic treatment and global cognitive function over one and two years in a cohort of patients with mild or moderate AD and identify potential differences in domain-specific cognitive outcomes within this cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of patients meeting the revised National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for mild or moderate AD, including patients both on treatment with a cholinesterase inhibitor and untreated controls (treated\u2009=\u200965, untreated\u2009=\u200965), were recruited from the Cognitive Neurology Clinic at Sunnybrook Health Sciences Centre, as part of the Sunnybrook Dementia Study. Patients were followed for one to two years and underwent standardized neuropsychological assessments to evaluate global and domain-specific cognitive function. Associations between cholinesterase inhibitor use and global and domain-specific cognitive outcome measures at one and two years of follow-up were estimated using mixed model linear regression, adjusting for age, education, and baseline mini mental state examination (MMSE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At one year, treated patients showed significantly less decline in global cognitive function, and treatment and time effects across tests of executive and visuospatial function. At two years, there was a significant trend towards less decline in global cognition for treated patients. Moreover, treated patients showed significant treatment and time effects across tests of executive functioning, memory, and visuospatial function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study offers two important contributions to knowledge of the effectiveness of cholinesterase inhibitor treatment in patients with mild-moderate AD: 1) that second-generation cholinesterase inhibitors demonstrate long-term effectiveness for reducing global cognitive decline over one to two years of follow-up, and 2) that decline in function for cognitive domains, including executive function, memory, and visuospatial skill that are primarily mediated by frontal networks and by the cholinergic system, rather than memory, may be slowed by treatment targeting the cholinergic system.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/alzrt280","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T05:01:05Z","timestamp":1408338065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment effects in multiple cognitive domains in Alzheimer\u2019s disease: a two-year cohort study"],"prefix":"10.1186","volume":"6","author":[{"given":"Pearl","family":"Behl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi D","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista L","family":"Lanctot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Streiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra E","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald T","family":"Stuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"267_CR1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra040223","volume":"351","author":"JL Cummings","year":"2004","unstructured":"Cummings JL: Alzheimer's disease. N Engl J Med. 2004, 351: 56-67. 10.1056\/NEJMra040223.","journal-title":"N Engl J Med"},{"key":"267_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1034\/j.1600-0404.2003.00097.x","volume":"108","author":"S Laatu","year":"2003","unstructured":"Laatu S, Revonsuo A, Jaykka H, Portin R, Rinne JO: Visual object recognition in early Alzheimer's disease: deficits in semantic processing. Acta Neurol Scand. 2003, 108: 82-89. 10.1034\/j.1600-0404.2003.00097.x.","journal-title":"Acta Neurol Scand"},{"key":"267_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/archneur.56.5.587","volume":"56","author":"SE Von","year":"1999","unstructured":"Von SE, Viitanen M, De RD, Winblad B, Fratiglioni L: Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol. 1999, 56: 587-592. 10.1001\/archneur.56.5.587.","journal-title":"Arch Neurol"},{"key":"267_CR4","first-page":"117","volume":"28","author":"MM Breteler","year":"1998","unstructured":"Breteler MM, Ott A, Hofman A: The new epidemic: frequency of dementia in the Rotterdam Study. Haemostasis. 1998, 28: 117-123.","journal-title":"Haemostasis"},{"key":"267_CR5","doi-asserted-by":"publisher","first-page":"v2","DOI":"10.1136\/jnnp.2005.082867","volume":"76","author":"WM Van der Flier","year":"2005","unstructured":"Van der Flier WM, Scheltens P: Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry. 2005, 76: v2-v7. 10.1136\/jnnp.2005.082867.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"267_CR6","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/cercor\/11.11.1083","volume":"11","author":"HL O'Brien","year":"2001","unstructured":"O'Brien HL, Tetewsky SJ, Avery LM, Cushman LA, Makous W, Duffy CJ: Visual mechanisms of spatial disorientation in Alzheimer's disease. Cereb Cortex. 2001, 11: 1083-1092. 10.1093\/cercor\/11.11.1083.","journal-title":"Cereb Cortex"},{"key":"267_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-2002-24990","volume":"23","author":"NS Foldi","year":"2002","unstructured":"Foldi NS, Lobosco JJ, Schaefer LA: The effect of attentional dysfunction in Alzheimer's disease: theoretical and practical implications. Semin Speech Lang. 2002, 23: 139-150. 10.1055\/s-2002-24990.","journal-title":"Semin Speech Lang"},{"key":"267_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0749-0690(05)70072-0","volume":"17","author":"LS Schneider","year":"2001","unstructured":"Schneider LS: Treatment of Alzheimer's disease with cholinesterase inhibitors. Clin Geriatr Med. 2001, 17: 337-358. 10.1016\/S0749-0690(05)70072-0.","journal-title":"Clin Geriatr Med"},{"key":"267_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16210","volume":"16","author":"M Bond","year":"2012","unstructured":"Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C: The effectiveness and cost effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease: a systematic review and economic model. Health Technol Assess. 2012, 16: 1-47.","journal-title":"Health Technol Assess"},{"key":"267_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","volume":"148","author":"P Raina","year":"2008","unstructured":"Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008, 148: 379-397. 10.7326\/0003-4819-148-5-200803040-00009.","journal-title":"Ann Intern Med"},{"key":"267_CR11","first-page":"211","volume":"3","author":"RA Hansen","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE: Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008, 3: 211-225.","journal-title":"Clin Interv Aging"},{"key":"267_CR12","first-page":"557","volume":"169","author":"KL Lanctot","year":"2003","unstructured":"Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Lanct\u00f4t KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR: Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003, 169: 557-564.","journal-title":"CMAJ"},{"key":"267_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/00019442-200407000-00003","volume":"12","author":"CW Ritchie","year":"2004","unstructured":"Ritchie CW, Ames D, Clayton T, Lai R: Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004, 12: 358-369. 10.1097\/00019442-200407000-00003.","journal-title":"Am J Geriatr Psychiatry"},{"key":"267_CR14","first-page":"1","volume":"25","author":"J Birks","year":"2006","unstructured":"Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006, 25: 1-","journal-title":"Cochrane Database Syst Rev"},{"key":"267_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/gps.1402","volume":"21","author":"A Takeda","year":"2006","unstructured":"Takeda A, Loreman E, Clegg A, Kirby J, Picot J, Payne E, Green C: Systematic review of the clinical effectiveness of donepezil, rivastigmine, and galantamine on cognition, quality of life and adverse events in Alzheimer disease. Intern J Geriat Psychiatry. 2006, 21: 17-28. 10.1002\/gps.1402.","journal-title":"Intern J Geriat Psychiatry"},{"key":"267_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.57.3.481","volume":"57","author":"RC Mohs","year":"2001","unstructured":"Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; \u201c312\u201d Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001, 57: 481-488. 10.1212\/WNL.57.3.481.","journal-title":"Neurology"},{"key":"267_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1212\/WNL.57.3.489","volume":"57","author":"B Winblad","year":"2001","unstructured":"Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P, Donepezil Nordic Study Group: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate. AD Neurology. 2001, 57: 489-495. 10.1212\/WNL.57.3.489.","journal-title":"AD Neurology"},{"key":"267_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000080972","volume":"19","author":"Y Karaman","year":"2005","unstructured":"Karaman Y, Erdogan F, Koseoglu E, Turan T, Ersoy AO: A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005, 19: 51-56. 10.1159\/000080972.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"267_CR19","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","volume":"363","author":"C Courtney","year":"2004","unstructured":"Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P, AD2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004, 363: 2105-2115.","journal-title":"Lancet"},{"key":"267_CR20","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","volume":"54","author":"MA Raskind","year":"2000","unstructured":"Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 2000, 54: 2261-2268. 10.1212\/WNL.54.12.2261.","journal-title":"Neurology"},{"key":"267_CR21","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1176\/ajp.151.3.390","volume":"151","author":"RG Stern","year":"1994","unstructured":"Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL: A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry March. 1994, 151: 390-396.","journal-title":"Am J Psychiatry March"},{"key":"267_CR22","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH: Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009, 302: 2557-2564. 10.1001\/jama.2009.1866.","journal-title":"JAMA"},{"key":"267_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pharmthera.2011.12.002","volume":"134","author":"HO Tayeb","year":"2012","unstructured":"Tayeb HO, Yang HD, Price BH, Tarazi FI: Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacother Ther. 2012, 134: 8-25. 10.1016\/j.pharmthera.2011.12.002.","journal-title":"Pharmacother Ther"},{"key":"267_CR24","first-page":"e31","volume":"3","author":"FJ Molnar","year":"2009","unstructured":"Molnar FJ, Man-Son-Hing M, Hulton B, Fergusson DA: Have last observation carried forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med. 2009, 3: e31-e50.","journal-title":"Open Med"},{"key":"267_CR25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp.72.3.310","volume":"72","author":"OL Lopez","year":"2002","unstructured":"Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST: Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002, 72: 310-314. 10.1136\/jnnp.72.3.310.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"267_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11920-004-0033-9","volume":"6","author":"PA Boyle","year":"2004","unstructured":"Boyle PA: Assessing and predicting functional impairment in Alzheimer's disease: the emerging role of frontal system dysfunction. Curr Psychiatry Rep. 2004, 6: 20-24. 10.1007\/s11920-004-0033-9.","journal-title":"Curr Psychiatry Rep"},{"key":"267_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1101\/lm.69204","volume":"11","author":"M Mesulam","year":"2004","unstructured":"Mesulam M: The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn Mem. 2004, 11: 43-49. 10.1101\/lm.69204.","journal-title":"Learn Mem"},{"key":"267_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0166-4328(97)86040-8","volume":"83","author":"TW Robbins","year":"1997","unstructured":"Robbins TW, McAlonan G, Muir JL, Everitt BJ: Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav Brain Res. 1997, 83: 15-23. 10.1016\/S0166-4328(97)86040-8.","journal-title":"Behav Brain Res"},{"key":"267_CR29","first-page":"77","volume-title":"Geriatric Psychiatry","author":"S Mattis","year":"1976","unstructured":"Mattis S: Mental status examination for organic mental syndrome in the elderly patient. Geriatric Psychiatry. Edited by: Bellak L, Karasu TB. 1976, New York: Grune and Stratton, 77-121."},{"key":"267_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2174\/156720506776383031","volume":"3","author":"P Behl","year":"2006","unstructured":"Behl P, Lanctot KL, Streiner DL, Guimont I, Black SE: Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the sunnybrook dementia cohort. Curr Alzheimer Res. 2006, 3: 147-156. 10.2174\/156720506776383031.","journal-title":"Curr Alzheimer Res"},{"key":"267_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman B, Jack C, Kawas C, Klunk W, Koroshetz WJ, Manly J, Mayeux R, Mohs R, Morris J, Rossor M, Scheltens P, Carrillo M, Thies B, Weintraub S, Phelps C: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on Diagnostic Guidelines for Alzheimer's Disease. Alzheimers Dement. 2011, 7: 263-269. 10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"267_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1017\/S1041610208007540","volume":"20","author":"P Behl","year":"2008","unstructured":"Behl P, Lanctot KL, Streiner DL, Black SE: The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort. Int Psychogeriatrics. 2008, 20: 1141-1159. 10.1017\/S1041610208007540.","journal-title":"Int Psychogeriatrics"},{"key":"267_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0006-3223(88)90038-8","volume":"23","author":"GS Alexopoulos","year":"1998","unstructured":"Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for Depression in Dementia. Biol Psychiatry. 1998, 23: 271-284.","journal-title":"Biol Psychiatry"},{"key":"267_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR: \u2018Mini-mental state\u2019. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"267_CR35","volume-title":"The California Verbal Learning Test","author":"DC Delis","year":"1987","unstructured":"Delis DC, Kramer JH, Kaplan E, Ober BA: The California Verbal Learning Test. 1987, New York: Psychological Corporation"},{"key":"267_CR36","volume-title":"Wechsler Memory Scale \u2013 Revised manual","author":"D Wechsler","year":"1987","unstructured":"Wechsler D: Wechsler Memory Scale \u2013 Revised manual. 1987, San Antonio, TX: The Psychological Corporation"},{"key":"267_CR37","volume-title":"Neuropsychological Assessment","author":"MD Lezack","year":"1983","unstructured":"Lezack MD: Neuropsychological Assessment. 1983, New York: Oxford University Press"},{"key":"267_CR38","volume-title":"Wisconsin Card Sorting Test manual","author":"RK Heaton","year":"1981","unstructured":"Heaton RK: Wisconsin Card Sorting Test manual. 1981, Psychological Assessment Resources: Odessa, FL"},{"key":"267_CR39","volume-title":"A Compendium of Neuropsychological Tests","author":"O Spreen","year":"1991","unstructured":"Spreen O, Strauss E: A Compendium of Neuropsychological Tests. 1991, New York: Oxford University Press"},{"key":"267_CR40","volume-title":"The Boston Naming Test","author":"E Kaplan","year":"1978","unstructured":"Kaplan E, Goodglass H, Weintraub S: The Boston Naming Test. 1978, Boston: Lea and Febiger"},{"key":"267_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/13854049308401883","volume":"7","author":"J Corwin","year":"1993","unstructured":"Corwin J, Bylsma FW: Commentary (on Rey & Osterrieth). Clin Neuropsychol. 1993, 7: 15-21.","journal-title":"Clin Neuropsychol"},{"key":"267_CR42","volume-title":"Contributions to Neuropsychological Assessment","author":"AL Benton","year":"1983","unstructured":"Benton AL, Hamsher K, Varney NR, Benton AL, Sivan AB, Hamsher KS, Varney NR, Spreen O: Contributions to Neuropsychological Assessment. 1983, New York: Oxford University Press"},{"key":"267_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1037\/0033-2909.104.1.145","volume":"104","author":"BS Holland","year":"1988","unstructured":"Holland BS, Copenhaver M: D. Improved Bonferroni-type multiple testing procedures. Psychol Bull. 1988, 104: 145-149.","journal-title":"Psychol Bull"},{"key":"267_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/jnnp.2003.029074","volume":"75","author":"K Rockwood","year":"2004","unstructured":"Rockwood K: Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004, 75: 677-685. 10.1136\/jnnp.2003.029074.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"267_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1017\/S0317167100003917","volume":"32","author":"P Behl","year":"2005","unstructured":"Behl P, Stefurak T, Black SE: Cognitive markers of progression in Alzheimer's disease. Can J Neurol Sci. 2005, 32: 140-151.","journal-title":"Can J Neurol Sci"},{"key":"267_CR46","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1212\/WNL.40.8.1225","volume":"40","author":"DP Salmon","year":"1990","unstructured":"Salmon DP, Thal LJ, Butters N, Heindel WC: Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology. 1990, 40: 1225-1230. 10.1212\/WNL.40.8.1225.","journal-title":"Neurology"},{"key":"267_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","volume":"20","author":"G Wilcock","year":"2003","unstructured":"Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R, Kershaw P, GAL-GBR-2 Study Group: A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging. 2003, 20: 777-789. 10.2165\/00002512-200320100-00006.","journal-title":"Drugs Aging"},{"key":"267_CR48","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0028-3932(98)00017-7","volume":"36","author":"S Kohler","year":"1998","unstructured":"Kohler S, Black SE, Sinden M, Szekely C, Kidron D, Parker JL, K\u00f6hler S, Black SE, Sinden M, Szekely C, Kidron D, Parker JL, Foster JK, Moscovitch M, Winocour G, Szalai JP, Bronskill MJ: Memory impairments associated with hippocampal versus parahippocampal\u2013gyrus atrophy: an MR volumetry study in Alzheimer's disease. Neuropsychologia. 1998, 36: 901-914. 10.1016\/S0028-3932(98)00017-7.","journal-title":"Neuropsychologia"},{"key":"267_CR49","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/archneur.1997.00550180039010","volume":"54","author":"R Fama","year":"1997","unstructured":"Fama R, Sullivan EV, Shear PK, Marsh L, Yesavage JA, Tinklenberg JR, Fama R, Sullivan EV, Shear PK, Marsh L, Yesavage JA, Tinklenberg JR, Lim KO, Pfefferbaum A: Selective cortical and hippocampal volume correlates of Mattis Dementia Rating Scale in Alzheimer disease. Arch Neurol. 1997, 54: 719-728. 10.1001\/archneur.1997.00550180039010.","journal-title":"Arch Neurol"},{"key":"267_CR50","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/gps.1319","volume":"20","author":"NS Foldi","year":"2005","unstructured":"Foldi NS, White RE, Schaefer LA: Detecting effects of donepezil on visual selective attention using signal detection parameters in Alzheimer's disease. Int J Geriatr Psychiatry. 2005, 20: 485-488. 10.1002\/gps.1319.","journal-title":"Int J Geriatr Psychiatry"},{"key":"267_CR51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/BF02244644","volume":"110","author":"BJ Sahakian","year":"1993","unstructured":"Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R: Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. Psychopharmacology (Berl). 1993, 110: 395-401. 10.1007\/BF02244644.","journal-title":"Psychopharmacology (Berl)"},{"key":"267_CR52","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1097\/00001756-199506090-00017","volume":"6","author":"P Riekkinen Jr","year":"1995","unstructured":"Riekkinen P, Soininen H, Helkala EL, Partanen K, Laakso M, Vanhanen M, Riekkinen P, Soininen H, Helkala EL, Partanen K, Laakso M, Vanhanen M, Riekkinen P: Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease. Neuroreport. 1995, 6: 1297-1300. 10.1097\/00001756-199506090-00017.","journal-title":"Neuroreport"},{"key":"267_CR53","first-page":"1441","volume":"42","author":"S Nakano","year":"2001","unstructured":"Nakano S, Asada T, Matsuda H, Uno M, Takasaki M: Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med. 2001, 42: 1441-1445.","journal-title":"J Nucl Med"},{"key":"267_CR54","first-page":"42","volume":"56","author":"A Ueki","year":"2004","unstructured":"Ueki A, Shinjo H, Shimode H, Nakajima T, Morita Y: A study of the effect of donepezil hydrochloride on cognitive function in patients with dementia of Alzheimer's type using WAIS-R. No To Shinkei. 2004, 56: 42-48.","journal-title":"No To Shinkei"},{"key":"267_CR55","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1017\/CBO9781139174909.005","volume-title":"Models of Working Memory: Mechanisms of Active Maintenance and Executive Control","author":"AD Baddeley","year":"1999","unstructured":"Baddeley AD, Logie RH: Working memory: The multiple component model. Models of Working Memory: Mechanisms of Active Maintenance and Executive Control. Edited by: Mikaye A, Shah P. 1999, Cambridge: Cambridge University Press, 28-61."},{"key":"267_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11065-005-3583-7","volume":"15","author":"C Germano","year":"2005","unstructured":"Germano C, Kinsella GJ: Working memory and learning in early Alzheimer's disease. Neuropsychol Rev. 2005, 15: 1-10. 10.1007\/s11065-005-3583-7.","journal-title":"Neuropsychol Rev"},{"key":"267_CR57","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1001\/archneur.61.4.556","volume":"61","author":"MM Swanberg","year":"2004","unstructured":"Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL: Executive dysfunction in Alzheimer disease. Arch Neurol. 2004, 61: 556-560. 10.1001\/archneur.61.4.556.","journal-title":"Arch Neurol"},{"key":"267_CR58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0278-2626(03)00109-X","volume":"53","author":"F Borgo","year":"2003","unstructured":"Borgo F, Giovannini L, Moro R, Semenza C, Arcicasa M, Zaramella M: Updating and inhibition processes in working memory: a comparison between Alzheimer's type dementia and frontal lobe focal damage. Brain Cogn. 2003, 53: 197-201. 10.1016\/S0278-2626(03)00109-X.","journal-title":"Brain Cogn"},{"key":"267_CR59","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1037\/0882-7974.11.3.387","volume":"11","author":"DT Stuss","year":"1996","unstructured":"Stuss DT, Craik FI, Sayer L, Franchi D, Alexander MP: Comparison of older people and patients with frontal lesions: evidence from word list learning. Psychol Aging. 1996, 11: 387-395.","journal-title":"Psychol Aging"},{"key":"267_CR60","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0010-9452(08)70785-8","volume":"35","author":"F Collette","year":"1999","unstructured":"Collette F, Van der Linden M, Salmon E: Executive dysfunction in Alzheimer's disease. Cortex. 1999, 35: 57-72. 10.1016\/S0010-9452(08)70785-8.","journal-title":"Cortex"},{"key":"267_CR61","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0278-2626(01)80080-4","volume":"46","author":"TM Sgaramella","year":"2001","unstructured":"Sgaramella TM, Borgo F, Mondini S, Pasini M, Toso V, Semenza C: Executive deficits appearing in the initial stage of Alzheimer's disease. Brain Cogn. 2001, 46: 264-268. 10.1016\/S0278-2626(01)80080-4.","journal-title":"Brain Cogn"},{"key":"267_CR62","first-page":"342","volume":"16","author":"S Lopez-Pousa","year":"2001","unstructured":"Lopez-Pousa S, Vilalta-Franch J, Garre-Olmo J, Turon-Estrada A, Lozano-Gallego M, Hernandez-Ferrandiz M, L\u00f3pez-Pousa S, Vilalta-Franch J, Garre-Olmo J, Turon-Estrada A, Lozano-Gallego M, Hern\u00e0ndez-Ferr\u00e0ndiz M, Fajardo-Tibau C, Cruz-Reina MM: Effectiveness of donepezil on several cognitive functions in patients with Alzheimer's disease over 12\u00a0months. Neurologia. 2001, 16: 342-347.","journal-title":"Neurologia"},{"key":"267_CR63","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hup.702","volume":"20","author":"A Borkowska","year":"2005","unstructured":"Borkowska A, Ziolkowska-Kochan M, Rybakowski JK: One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests. Hum Psychopharmacol. 2005, 20: 409-414. 10.1002\/hup.702.","journal-title":"Hum Psychopharmacol"},{"key":"267_CR64","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/01688638608401312","volume":"8","author":"AM Johnson","year":"1996","unstructured":"Johnson AM, Gustafson L, Reisberg J: Behavioral observations durig performance of the WAIS Block Design Test related to abnormalities of regional blood flow in organic dementia. J Clin Exp Neuropsychol. 1996, 8: 201-209.","journal-title":"J Clin Exp Neuropsychol"},{"key":"267_CR65","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1080\/01688639108401088","volume":"13","author":"BA Ober","year":"1991","unstructured":"Ober BA, Jagust WJ, Koss E, Delis DC, Friedland RP: Visuoconstructive performance and regional cerebral glucose metabolism in Alzheimer's disease. J Clin Exp Neuropsychol. 1991, 13: 752-772. 10.1080\/01688639108401088.","journal-title":"J Clin Exp Neuropsychol"},{"key":"267_CR66","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00002093-200004000-00005","volume":"14","author":"E Vuorinen","year":"2000","unstructured":"Vuorinen E, Laine M, Rinne J: Common pattern of language impairment in vascular dementia and in Alzheimer disease. Alzheimer Dis Assoc Disord. 2000, 14: 81-86. 10.1097\/00002093-200004000-00005.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"267_CR67","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/01688639508405137","volume":"17","author":"PR van der Hurk","year":"1995","unstructured":"van der Hurk PR, Hodges JR: Episodic and semantic memory in Alzheimer's disease and progressive supranuclear palsy: a comparative study. J Clin Exp Neuropsychol. 1995, 17: 459-471. 10.1080\/01688639508405137.","journal-title":"J Clin Exp Neuropsychol"},{"key":"267_CR68","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awg128","volume":"126","author":"MP Alexander","year":"2003","unstructured":"Alexander MP, Stuss DT, Fansabedian N: California Verbal Learning Test: performance by patients with focal frontal and non-frontal lesions. Brain. 2003, 126: 1493-1503. 10.1093\/brain\/awg128.","journal-title":"Brain"},{"key":"267_CR69","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/0028-3932(95)00151-4","volume":"34","author":"JD Greene","year":"1996","unstructured":"Greene JD, Baddeley AD, Hodges JR: Analysis of the episodic memory deficit in early Alzheimer's disease: evidence from the doors and people test. Neuropsychologia. 1996, 34: 537-551. 10.1016\/0028-3932(95)00151-4.","journal-title":"Neuropsychologia"},{"key":"267_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1037\/0882-7974.12.1.183","volume":"12","author":"E Grober","year":"1997","unstructured":"Grober E, Kawas C: Learning and retention in preclinical and early Alzheimer's disease. Psychol Aging. 1997, 12: 183-188.","journal-title":"Psychol Aging"},{"key":"267_CR71","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1017\/S1355617701755105","volume":"7","author":"MS Albert","year":"2001","unstructured":"Albert MS, Moss MB, Tanzi R, Jones K: Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc. 2001, 7: 631-639. 10.1017\/S1355617701755105.","journal-title":"J Int Neuropsychol Soc"},{"key":"267_CR72","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/0891988705284711","volume":"19","author":"TA Crowell","year":"2006","unstructured":"Crowell TA, Paramadevan J, Abdullah L, Mullan M: Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings. J Geriatr Psychiatry Neurol. 2006, 19: 13-15. 10.1177\/0891988705284711.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"267_CR73","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1037\/0894-4105.12.4.565","volume":"12","author":"K Lukatela","year":"1998","unstructured":"Lukatela K, Malloy P, Jenkins M, Cohen R: The naming deficit in early Alzheimer's and vascular dementia. Neuropsychology. 1998, 12: 565-572.","journal-title":"Neuropsychology"},{"key":"267_CR74","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S1355617798002653","volume":"4","author":"DT Stuss","year":"1998","unstructured":"Stuss DT, Alexander MP, Hamer L, Palumbo C, Dempster R, Binns M, Stuss DT, Alexander MP, Hamer L, Palumbo C, Dempster R, Binns M, Levine B, Izukawa D: The effects of focal anterior and posterior brain lesions on verbal fluency. J Int Neuropsychol Soc. 1998, 4: 265-278.","journal-title":"J Int Neuropsychol Soc"},{"key":"267_CR75","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1136\/jnnp.57.11.1389","volume":"57","author":"A Rosser","year":"1994","unstructured":"Rosser A, Hodges JR: Initial letter and semantic category fluency in Alzheimer's disease, Huntington's disease, and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1994, 57: 1389-1394. 10.1136\/jnnp.57.11.1389.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"267_CR76","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jnnp.58.1.81","volume":"58","author":"F Pasquier","year":"1995","unstructured":"Pasquier F, Lebert F, Grymonprez L, Petit H: Verbal fluency in dementia of frontal lobe type and dementia of Alzheimer type. J Neurol Neurosurg Psychiatry. 1995, 58: 81-84. 10.1136\/jnnp.58.1.81.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"267_CR77","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/S0028-3932(99)00032-9","volume":"37","author":"JG Keilp","year":"1996","unstructured":"Keilp JG, Gorlyn M, Alexander GE, Stern Y, Prohovnik I: Cerebral blood flow patterns underlying the differential impairment in category vs letter fluency in Alzheimer's disease. Neuropsychologia. 1996, 37: 1251-1261.","journal-title":"Neuropsychologia"},{"key":"267_CR78","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/brain\/115.3.711","volume":"115","author":"R Parasuraman","year":"1992","unstructured":"Parasuraman R, Greenwood PM, Haxby JV, Grady CL: Visuospatial attention in dementia of the Alzheimer Type. Brain. 1992, 115: 711-733. 10.1093\/brain\/115.3.711.","journal-title":"Brain"},{"key":"267_CR79","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1017\/S0033291700024867","volume":"17","author":"B Sahakian","year":"1987","unstructured":"Sahakian B, Joyce E, Lishman WA: Cholinergic effects on constructional abilities and on mnemonic processes: a case report. Psychol Med. 1987, 17: 329-333. 10.1017\/S0033291700024867.","journal-title":"Psychol Med"},{"key":"267_CR80","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1046\/j.1468-1331.2003.00757.x","volume":"11","author":"O Almkvist","year":"2004","unstructured":"Almkvist O, Darreh-Shori T, Stefanova E, Spiegel R, Nordberg A: Preserved cognitive function after 12\u00a0months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients. Eur J Neurol. 2004, 11: 253-261. 10.1046\/j.1468-1331.2003.00757.x.","journal-title":"Eur J Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/alzrt280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/alzrt280\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/alzrt280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:04:47Z","timestamp":1728907487000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/alzrt280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,8]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1186\/alzrt280","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,18]]},"assertion":[{"value":"10 May 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"48"}}